Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Crohn Disease | 4 | 2012 | 29 | 0.770 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2019 | 29 | 0.490 |
Why?
|
| Colitis, Ulcerative | 3 | 2006 | 24 | 0.480 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2005 | 22 | 0.390 |
Why?
|
| Capsule Endoscopy | 1 | 2012 | 3 | 0.380 |
Why?
|
| Intestinal Diseases | 1 | 2012 | 16 | 0.370 |
Why?
|
| Intestine, Small | 1 | 2012 | 40 | 0.370 |
Why?
|
| Colonoscopy | 2 | 2001 | 45 | 0.330 |
Why?
|
| Uvula | 1 | 2009 | 1 | 0.310 |
Why?
|
| Enteral Nutrition | 1 | 2010 | 28 | 0.310 |
Why?
|
| Endoscopy, Digestive System | 1 | 2009 | 10 | 0.310 |
Why?
|
| Lymphomatoid Papulosis | 1 | 2009 | 2 | 0.310 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 69 | 0.300 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2008 | 10 | 0.290 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 101 | 0.280 |
Why?
|
| Early Detection of Cancer | 1 | 2008 | 101 | 0.270 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 241 | 0.260 |
Why?
|
| Skin Neoplasms | 1 | 2009 | 217 | 0.250 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 16 | 0.250 |
Why?
|
| Colorectal Neoplasms | 1 | 2008 | 222 | 0.240 |
Why?
|
| Pyrazoles | 1 | 2006 | 68 | 0.240 |
Why?
|
| Sulfonamides | 1 | 2006 | 67 | 0.240 |
Why?
|
| Esophagoscopy | 1 | 2005 | 18 | 0.220 |
Why?
|
| Esophageal Neoplasms | 1 | 2005 | 39 | 0.220 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2005 | 158 | 0.200 |
Why?
|
| Thioguanine | 1 | 2003 | 2 | 0.190 |
Why?
|
| Azathioprine | 1 | 2003 | 25 | 0.190 |
Why?
|
| Humans | 18 | 2019 | 33035 | 0.190 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 300 | 0.180 |
Why?
|
| Registries | 2 | 2019 | 321 | 0.180 |
Why?
|
| Cytomegalovirus | 1 | 2001 | 31 | 0.180 |
Why?
|
| Cytomegalovirus Infections | 1 | 2001 | 49 | 0.180 |
Why?
|
| Diverticulum, Colon | 1 | 2001 | 1 | 0.170 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 4071 | 0.170 |
Why?
|
| Adult | 8 | 2019 | 9607 | 0.170 |
Why?
|
| Colonic Diseases | 1 | 2000 | 4 | 0.160 |
Why?
|
| Diverticulum | 1 | 2000 | 11 | 0.160 |
Why?
|
| Postpartum Period | 1 | 2019 | 37 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2019 | 42 | 0.140 |
Why?
|
| Preventive Health Services | 1 | 2019 | 44 | 0.140 |
Why?
|
| Male | 10 | 2019 | 19789 | 0.140 |
Why?
|
| Placebos | 2 | 2010 | 63 | 0.140 |
Why?
|
| Aged | 8 | 2019 | 10659 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2019 | 182 | 0.140 |
Why?
|
| Vaccination | 1 | 2019 | 146 | 0.130 |
Why?
|
| Retrospective Studies | 4 | 2012 | 3710 | 0.130 |
Why?
|
| Young Adult | 3 | 2019 | 2749 | 0.130 |
Why?
|
| Middle Aged | 7 | 2019 | 12229 | 0.120 |
Why?
|
| Female | 8 | 2019 | 20413 | 0.100 |
Why?
|
| Duodenoscopy | 1 | 2012 | 1 | 0.090 |
Why?
|
| Gastroscopy | 1 | 2012 | 8 | 0.090 |
Why?
|
| Linoleic Acids, Conjugated | 1 | 2012 | 7 | 0.090 |
Why?
|
| Intestines | 2 | 2009 | 60 | 0.090 |
Why?
|
| Adolescent | 3 | 2019 | 3647 | 0.080 |
Why?
|
| Placebo Effect | 1 | 2010 | 14 | 0.080 |
Why?
|
| Necrosis | 1 | 2009 | 51 | 0.080 |
Why?
|
| Patient Compliance | 2 | 2019 | 219 | 0.080 |
Why?
|
| Image Enhancement | 1 | 2009 | 70 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2290 | 0.080 |
Why?
|
| Immunocompromised Host | 1 | 2009 | 51 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2012 | 566 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2019 | 2343 | 0.070 |
Why?
|
| Child, Preschool | 1 | 2012 | 1282 | 0.070 |
Why?
|
| Logistic Models | 1 | 2010 | 785 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 541 | 0.070 |
Why?
|
| Mesalamine | 1 | 2006 | 2 | 0.060 |
Why?
|
| Child | 1 | 2012 | 2479 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2005 | 23 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2005 | 61 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2005 | 185 | 0.050 |
Why?
|
| Abdominal Neoplasms | 1 | 2004 | 13 | 0.050 |
Why?
|
| Age Distribution | 1 | 2005 | 201 | 0.050 |
Why?
|
| Abdominal Wall | 1 | 2004 | 22 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2008 | 1855 | 0.050 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2004 | 28 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 1315 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 472 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 576 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 531 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2010 | 3462 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2001 | 24 | 0.040 |
Why?
|
| Incidence | 1 | 2005 | 1253 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 412 | 0.040 |
Why?
|
| Acute Disease | 1 | 2001 | 263 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2000 | 65 | 0.040 |
Why?
|
| Comorbidity | 1 | 2001 | 573 | 0.040 |
Why?
|
| Documentation | 1 | 2019 | 47 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2005 | 1470 | 0.040 |
Why?
|
| Prevalence | 1 | 2001 | 1003 | 0.040 |
Why?
|
| Hospitalization | 1 | 2001 | 495 | 0.040 |
Why?
|
| Risk Factors | 1 | 2003 | 4015 | 0.030 |
Why?
|
| Prognosis | 1 | 2019 | 1550 | 0.030 |
Why?
|
| United States | 1 | 2001 | 4137 | 0.020 |
Why?
|
| Immunity | 1 | 2012 | 20 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2012 | 44 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2012 | 26 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2012 | 59 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 55 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 59 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 189 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2012 | 97 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 213 | 0.020 |
Why?
|
| Quality of Life | 1 | 2012 | 977 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2006 | 120 | 0.010 |
Why?
|